Funded Expressions of Interest
1 July 2013 to 31 December 2014
Associate Professor David Anderson. Burnet Institute. Plasma collection/drying device to facilitate
HIV viral load testing for patients in remote settings.
Professor James Beeson. Burnet Institute. Carbohydrate inhibitors of HIV - potential microbicides
and therapeutics.
Dr. Rob Center. The University of Melbourne. Targeting HIV immunogens to immune cells to
enhance vaccine efficacy
Professor Anthony Cunningham. Westmead Millennium Institute for Medical Research.
Development of small molecule inhibitors of HIV envelope-Langerin interactions and of HIV uptake
by Langerhans Cells (LCs) as topical (genital) microbicides.
Dr. Russel Diefenbach. Westmead Millennium Institute for Medical Research. Development of
inhibitors that target dynein-dependent transport of HIV.
Professor Christian Doerig. Monash University. Human protein kinases essential for hepatitis C
virus replication.
Dr. Mark Douglas. The University of Sydney. A Pilot Study of Fenofibrate to Improve Hepatitis C
Virus Treatment Response.
Associate Professor Heidi Drummer. Burnet Institute. Production and evaluation of a CHO cell
derived Delta3 HCV vaccine candidate.
Dr. Lloyd Einsiedel. Flinders University. The influence of infection with the human T lymphocyte
virus Type 1 on clinical outcomes, virological features and biomarkers of chronic hepatitis B virus
infection in an indigenous Australian population.
Dr. Nicholas Eyre. University of Adelaide. Hepatitis C virus NS5A protein phosphorylation as a target
of antiviral drug development.
Dr. Karla Helbig. University of Adelaide. Improving treatment outcomes in individuals with chronic
HCV and steatosis.
Professor Paul Hertzog. Monash University. Defining the anti-HIV activity of interferon epsilon - a
reproductive tract-specific, hormone-regulated type 1 interferon.
Professor Mark Hogarth. Burnet Institute. A method of measuring HIV specific immune complexes
and correlation with vaccine responses and disease outcome.
Professor Stephen Kent. The University of Melbourne. Antibody protection against cell-associated
Dr. Marit Kramski. The University of Melbourne. Antibody-dependent cel ular cytotoxicity boosting
therapeutic vaccines to purge the HIV reservoir.
Dr. Michaela Lucas. Murdoch University. T cell and B cell responses to the Delta3 HCV vaccine
Dr. Clovis Palmer. Burnet Institute. Predicting the rate of CD4+ T cell decline in HIV infected adults.
Dr. Rebecca Pavlos. Murdoch University. HLA - Associated drug hypersensitivities: Functional basis
of clinical phenotyes and applications to safer drug development.
Dr. Pantelis Poumbourios. Burnet Institute. Novel HIV-1-like particle vaccine with enhanced
presentation of broadly neutralizing antibody epitopes.
Associate Professor Damian Purcel . The University of Melbourne. Optimizing new drugs targeting
HIV-1 viral latency.
Dr. Charani Ranasinghe. The Australian National University. Validation of an effective HIV vaccine
for pre-clinical evaluation.
Professor Andreas Suhrbier. QIMR Berghofer Medical Research Institute. EcoHIV, a convenient,
biosafety level 2, mouse model for animal testing of HIV vaccines and anti-retroviral drugs.
Associate Professor Kumar Visvanathan. The University of Melbourne. Interferon stimulating gene
(ISG) induction in the liver of HCV infected patients pre and post treatment.
Dr. Nadia Warner. Melbourne Health. NTCP-HepG2 cells - Establishing a model system for HBV
infection, fitness and cccDNA.
Associate Professor Amany Zekry. University of New South Wales. T-cell metabolic pathways as a
predictor of anti-HCV T-cell immune response and outcomes after primary HCV infection.


Convenience time policy

Associate Discount I. OVERVIEW Chico’s FAS, Inc. provides our associates and eligible family members a discount off merchandise purchased in all Chico’s FAS, Inc. Boutiques (Chico’s, White House|Black Market and Soma) as well as merchandise purchased via Chico’s FAS websites. The Boston Proper Associate Discount is only offered to Associates located at the Fort Myers National

Thalidomide, inn-lenalidomid

SUMMARY OF PRODUCT CHARACTERISTICS NAME OF THE MEDICINAL PRODUCT Thalidomide Celgene 50 mg hard capsules 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each capsule contains 50 mg of thalidomide. Excipient: Each capsule contains 257.2 mg of anhydrous lactose. For a full list of excipients, see section 6.1. 3. PHARMACEUTICAL Hard capsule. White opaque capsules marked

Copyright © 2018 Predicting Disease Pdf